WCO-IOF: Rituximab positively impacts QOL in patients with rheumatoid arthritis .
Effect of rituximab therapy on life quality with rheumatoid arthritis patients
98 patients diagnosed with rheumatoid arthritis (RA) were randomized to receive methotrexate with or without rituximab therapy to determine effect of rituximab on quality of life in this patient population. The Euro-QOL 5 dimension (EQ-5D) and Health Assessment Questionnaire for Rheumatoid Arthritis (HAQ) were assessed over 24 months. Upon analysis, combined methotrexate and rituximab therapy achieved satisfactory therapeutic effects and pronounced clinical benefits, while effects with methotrexate alone were minimal.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
